TriSalus Life Sciences, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
TLSI$2.85-11.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit
(unaudited, in thousands except share data)
| Three Months Ended March 31, 2026 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Preferred stock · Common stock · Additional paid-in capital · Accumulated deficit · Total | |||||||||||||||||
| Shares · Amount · Shares · Amount | |||||||||||||||||
| Balance as of December 31, 2025 | — | $— | 49,997,836 | $4 | $296,718 | $(330,583) | $(33,861) | ||||||||||
| Net income | — | — | — | — | — | 1,539 | 1,539 | ||||||||||
| Exercise of options and vesting of restricted stock units (1) | — | — | 152,877 | — | 32 | — | 32 | ||||||||||
| Issuance of common stock through employee stock purchase plan (1) | — | — | 44,127 | — | — | — | — | ||||||||||
| Stock-based compensation | — | — | — | — | 2,472 | — | 2,472 | ||||||||||
| Proceeds from the issuance of common stock, net of issuance costs | — | — | 11,219,515 | 1 | 42,624 | — | 42,625 | ||||||||||
| Balance as of March 31, 2026 | — | $— | 61,414,355 | $5 | $341,846 | $(329,044) | $12,807 | ||||||||||
| Three Months Ended March 31, 2025 | |||||||||||||||||
| Preferred stock · Common stock · Additional paid-in capital · Accumulated deficit · Total | |||||||||||||||||
| Shares · Amount · Shares · Amount | |||||||||||||||||
| Balance as of December 31, 2024 | 3,985,002 | $— | 31,279,264 | $3 | $253,652 | $(279,549) | $(25,894) | ||||||||||
| Net loss | — | — | — | — | — | (10,375) | (10,375) | ||||||||||
| Exercise of options and vesting of restricted stock units (1) | — | — | 159,699 | — | 279 | — | 279 | ||||||||||
| Issuance of common stock through employee stock purchase plan (1) | — | — | 55,670 | — | — | — | — | ||||||||||
| Stock-based compensation | — | — | — | — | 1,620 | — | 1,620 | ||||||||||
| Preferred stock conversion | (365,000) | — | 777,829 | — | — | — | — | ||||||||||
| Balance as of March 31, 2025 | 3,620,002 | $— | 32,272,462 | $3 | $255,551 | $(289,924) | $(34,370) | ||||||||||
| (1) The Company records the issuance of the shares when they are recorded by the transfer agent and as such, there could be timing differences between when the expense is recorded and shares are transferred. | |||||||||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.